Read More Pharma Industry News Vaxcyte’s $1bn Thermo Fisher deal: Can new U.S. vaccine capacity secure its PCV future? Vaxcyte partners with Thermo Fisher in a $1B deal to build U.S. fill-finish vaccine capacity. Find out why this matters for its PCV pipeline and investors. byPallavi MadhirajuSeptember 30, 2025